The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer-related deaths. Surgical resection is the primary treatment, with laparoscopic-assisted gastrectomy (LG) being a minimally invasive option. However, LG is limited by restricted instrument mobility and hand tremors, which affect precision. The Da Vinci robotic system enhances surgical precision with 3D magnification, improved hand-eye coordination, tremor filtration, and flexible instruments. It is especially beneficial in complex procedures like D2 lymph node dissection and lower mediastinal lymph node clearance. Unlike laparoscopic surgery, robotic surgery offers superior flexibility and reduced pancreatic injury during dissection. Robotic-assisted gastrectomy (RG) offers advantages over LG, such as reduced blood loss, shorter hospital stays, and improved lymph node dissection. However, its short-term benefits remain debated, and most studies focus on early gastric cancer. The safety and efficacy of RG for advanced gastric cancer are not well-established. Vascular coagulation is crucial in minimally invasive surgery. Ultrasonic devices, though widely used, can cause thermal damage due to high temperatures. In contrast, the Vessel Sealer Extend (VSE) offers greater flexibility and precision. It allows 540° instrument rotation, coagulates vessels up to 7 mm in diameter with lower energy, and minimizes thermal injury. Retrospective studies show RG with VSE may have faster recovery and fewer complications than LG. However, further prospective, multicenter studies are needed to confirm these benefits for advanced gastric cancer. The investigators propose a multicenter, observational study to evaluate RG with VSE in advanced gastric cancer, assessing safety, recovery, and oncological outcomes.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Potwierdzona biopsją raka żołądka typu gruczolakowatego
- •Nowotwór stadium zaawansowanego (T2-4a) bez przerzutów odległych
- •Przeprowadzone przedoperacyjne badania tomograficzne brzucha i klatki piersiowej bez cech przerzutów
- •Ogólny stan zdrowia pozwalający na operację (ECOG 0-1)
- •Zdolność do przyjęcia znieczulenia (ASA klasa I-III)
- •Pisemna zgoda na udział w badaniu
✗ Disqualifies
- •Wiele pierwotnych raków żołądka lub raków w innych miejscach
- •Wcześniejsza operacja w górnym brzuchu (poza usunięciem pęcherzyka żółciowego)
- •Wcześniejsza operacja żołądka
- •Brak przedoperacyjnych badań obrazowych lub niekompletne określenie stopnia zaawansowania raka
- •Powiększone węzły chłonne powyżej 3 cm
- •Inne nowotwory w ciągu ostatnich 5 lat
- •Wcześniejsza chemioterapia lub radioterapia
- •Poważne problemy z sercem, mózgiem lub innymi narządami w ostatnich 6 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 31, 2026
- Sex
- No restrictions
Locations (1)
First Hospital of Jilin University
Changchun, China
Trial contact
Quan Wang, Professor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.